FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with applying fulvestrant as a curative preparation of the third line in treating patients with resistant cancer of mammary gland after failed application of tamoxifen and aromatase inhibitor. The innovation shows positive therapeutic result in 41% cases.
EFFECT: higher sensitivity to fulvestrant.
5 cl, 1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION COMPRISING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRILYL)-2-PYRIDINEAMINE AND CHEMOTHERAPEURIC AGENT | 2002 |
|
RU2318517C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT | 2014 |
|
RU2805145C2 |
| COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2680714C2 |
| APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER | 2021 |
|
RU2806277C1 |
| COMBINATIONS INCLUDING EPOTHILONES AND THEIR PHARMACEUTICAL APPLICATION | 2003 |
|
RU2379032C9 |
| PHARMACEUTICAL COMBINATION COMPRISING INHIBITOR PHOSPHATYLENOSITOL 3-KINASES AND AROMATASE INHIBITOR | 2013 |
|
RU2651023C2 |
| USE OF ANASTROZOLE IN WOMEN TREATMENT IN POST-CLIMACTERIC PERIOD SUFFERING FROM BREAST EARLY CANCER | 2002 |
|
RU2320339C2 |
| METHOD OF CANCER TREATMENT | 2005 |
|
RU2361589C2 |
| USING ERIBULIN FOR TREATING BREAST CANCER | 2013 |
|
RU2689977C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
